From April 2019, the NHS will provide the technology for one in five of those with type 1 diabetes in England. Patients will be able to receive it on prescription from their local GP or diabetes team. Those who qualify include:
•People with type 1 diabetes who need intensive monitoring (>8 times every day) as demonstrated in a review over the past 3 months.
•People with diabetes associated with cystic fibrosis on insulin.
•Pregnant women with type 1 diabetes for 12 months in total.
•People with type 1 diabetes unable to routinely self-monitor blood glucose due to disability.
•People with type 1 diabetes for whom the specialist diabetes MDT determines have occupational or psychosocial circumstances that warrant a 6-month trial of Libre with appropriate support.